Please use this identifier to cite or link to this item:
http://223.31.159.10:8080/jspui/handle/123456789/1805Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kaushik, Love | - |
| dc.contributor.author | Vivek, A T | - |
| dc.contributor.author | Arora, Simran | - |
| dc.contributor.author | Hamid, Fiza | - |
| dc.contributor.author | Mukherjee, Kanka | - |
| dc.contributor.author | Bisht, Niyati | - |
| dc.contributor.author | Chaudhary, Sakshi | - |
| dc.contributor.author | Shukla, Jagriti | - |
| dc.contributor.author | Nawani, Sakshi | - |
| dc.contributor.author | Kumar, Shailesh | - |
| dc.date.accessioned | 2026-04-20T10:34:13Z | - |
| dc.date.available | 2026-04-20T10:34:13Z | - |
| dc.date.issued | 2026 | - |
| dc.identifier.citation | Progress in Molecular Biology and Translational Science, 221: 71-97 | en_US |
| dc.identifier.issn | 1877-1173 | - |
| dc.identifier.other | https://doi.org/10.1016/bs.pmbts.2026.01.013 | - |
| dc.identifier.uri | https://www.sciencedirect.com/science/chapter/bookseries/abs/pii/S187711732600013X | - |
| dc.identifier.uri | http://223.31.159.10:8080/jspui/handle/123456789/1805 | - |
| dc.description | Accepted date: 13 April 2026 | en_US |
| dc.description.abstract | AI and genomics are revolutionizing precision medicine by using machine learning (ML) to analyze large-scale next-generation sequencing (NGS) data, identifying genetic mutations and biomarkers for personalized therapies. In practice, this accelerates drug discovery and enhances variant detection, while in cancer genomics, AI enables early detection via liquid biopsies and refines treatment by integrating multi-omics data to improve therapeutic precision. However, challenges such as data biases in underrepresented populations, limited model interpretability, and ethical concerns regarding privacy and algorithmic inequity hinder clinical adoption and demand robust governance. Efforts to diversify datasets also face standardization hurdles, although explainable AI and federated learning provide promising solutions for improving transparency and privacy. In this chapter, we discuss the role of AI in advancing genomics from diagnostics to novel therapies and emphasize the need for equitable frameworks to ensure responsible implementation, thereby paving the way for breakthroughs in personalized medicine. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | Elsevier B.V. | en_US |
| dc.subject | Artificial intelligence | en_US |
| dc.subject | Drug discovery | en_US |
| dc.subject | Genomics | en_US |
| dc.subject | Machine learning | en_US |
| dc.subject | Multi-omics | en_US |
| dc.subject | Precision medicine | en_US |
| dc.title | The intersection of AI and genomics in health and disease: Advancements and applications | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Institutional Publications | |
Files in This Item:
There are no files associated with this item.
Items in IR@NIPGR are protected by copyright, with all rights reserved, unless otherwise indicated.